scholarly journals Treatment of Facial Basal Cell Carcinoma: A Review

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Vanessa Smith ◽  
Shernaz Walton
Keyword(s):  
Basal Cell ◽  
Treatment Options ◽  
Evidence Base ◽  
Treatment Modalities ◽  
Western World ◽  
Common Risk Factor ◽  
Randomized Controlled ◽  
High Incidence ◽  
Basal Cell Carcinomas ◽  
Good Cosmetic

Basal cell carcinomas (BCCs) are locally destructive malignancies of the skin. They are the most common type of cancer in the western world. The lifetime incidence may be up to 39%. UV exposure is the most common risk factor. The majority of these tumours occur on the head and neck. Despite BCCs being relatively indolent the high incidence means that their treatment now contributes a significant and increasing workload for the health service. A good understanding of the options available is important. Management decisions may be influenced by various factors including the patient's age and comorbidities and the lesion subtype and location. Due to the importance of a good cosmetic and curative outcome for facial BCCs treatment decisions may differ significantly to those that would be made for BCCs arising elsewhere. There is little good randomized controlled data available comparing treatment modalities. Although traditionally standard excision has been the treatment of choice various other options are available including: Mohs micrographic surgery, curettage and cautery, cryosurgery, radiotherapy, topical imiquimod, photodynamic therapy and topical 5-fluorouracil. We discuss and review the literature and evidence base for the treatment options that are currently available for facial BCCs.

scholarly journals Treatment Options for Vestibular Migraine

US Neurology ◽  
2016 ◽  
Vol 12 (01) ◽  
pp. 39 ◽  
Author(s):  
Steffen Naegel ◽  
◽  
Manjit Matharu ◽  
Mark Obermann ◽  
◽  
...  
Keyword(s):  
Prophylactic Treatment ◽  
International Headache Society ◽  
Controlled Trial ◽  
Treatment Options ◽  
Evidence Base ◽  
Vestibular Migraine ◽  
Controlled Trials ◽  
Common Cause ◽  
Randomized Controlled ◽  
Trial Testing

Although vestibular migraine is a common cause of vertigo, affecting approximately 1% of the Western world’s population, it remains widely under-recognized and is under-diagnosed. Diagnostic criteria for vestibular migraine were recently published in collaboration with the International Headache Society and the Bárány-Society. Trials investigating the treatment of vestibular migraine are sparse but some are now underway. This review focuses on the treatments options available for vestibular migraine, based on the existing evidence base where available. Regarding acute treatments, there are two randomized controlled trials that provide evidence for the use of triptans (zolmitriptan and rizatriptan) for the management of vestibular migraine attacks. For prophylactic treatment, the evidence base is largely non-existent, since the only multicenter randomized placebo-controlled trial testing metoprolol versus placebo is still underway. Consequently, the treatment recommendations for the prophylactic treatment of vestibular migraine are mainly based on expert opinion and the treatments guidelines for migraine with and without aura.

A 5-Year Review of 1220 Malignant Periocular Tumours in an English County

2021 ◽  
Author(s):  
Zhiheng Lin ◽  
Umair Sheikh ◽  
Laszlo Igali ◽  
Bridget Hemmant
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Lower Eyelid ◽  
National Average ◽  
Caucasian Population ◽  
Excision Biopsy ◽  
High Incidence ◽  
Basal Cell Carcinomas ◽  
The Uk

Abstract PURPOSE: To determine the incidence, proportion and location of periocular tumours in an English county over a five year period, and compare to other studies in the UK and worldwide.METHODS: A retrospective review of histopathology reports was performed for all periocular excision biopsy of malignancies from the county’s three main hospitals over a 5-year period. These hospitals cover a population of just over one million. Tumours were classified according to type and location. RESULTS:1220 lesions were included in this study. Right-sided lesions were more common than left. The incidence of basal cell carcinoma was 22 per 100,000 and squamous cell carcinoma 1.3 per 100,000, which were found most commonly on the lower eyelid and eyebrow respectively. The incidence of all other types of lesions was less than 0.5 per 100,000 per year. CONCLUSION:The incidence of periocular basal cell carcinomas in the predominantly elderly Caucasian population was at least three times the published national average. The high incidence of periocular tumours in this East of England county is set to increase further as the proportion of over 65 year olds in the population is set to nearly double within two decades.

Basal Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Sun Exposure ◽  
Hedgehog Pathway ◽  
Treatment Modalities ◽  
Genetic Syndromes

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of basal cell carcinoma (BCC). The development of BCC is thought to arise from intense, intermittent sun exposure leading to burns. Identifying patients with high-risk factors for developing BCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of BCC include cure of tumor with maximal preservation of function. Although rarely metastatic, BCC can produce substantial local destruction. Treatment modalities can be divided into surgical and nonsurgical therapies, although surgical therapy is the mainstay of treatment. Superficial therapies, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, or cryotherapy, may be effective for anatomically challenging locations where surgery or radiation is contraindicated, but the cure rates of these approaches are lower compared with surgery. Recent FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib for patients who have exhausted surgical and radiation options for treating advanced BCC. This review contains 4 figures, 5 tables, and 25 references. Key words: cryosurgery, cutaneous basal cell carcinoma, hedgehog pathway inhibitors, Mohs micrographic surgery, pathologic risk factors, photodynamic therapy, radiation therapy, surgical margins, topical therapies 

Basal Cell Carcinoma: Epidemiology, Risk Factors, and Treatment Options

2017 ◽  
Author(s):  
Jeffrey M Farma ◽  
Elena P Lamb
Keyword(s):  
Risk Factors ◽  
Photodynamic Therapy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Sun Exposure ◽  
Hedgehog Pathway ◽  
Treatment Modalities ◽  
Genetic Syndromes

Ultraviolent (UV) solar radiation is considered to be the dominant risk factor for development of basal cell carcinoma (BCC). The development of BCC is thought to arise from intense, intermittent sun exposure leading to burns. Identifying patients with high-risk factors for developing BCC includes chronic immunosuppression, exposure to ionizing radiation, and certain genetic syndromes. Primary treatment goals of BCC include cure of tumor with maximal preservation of function. Although rarely metastatic, BCC can produce substantial local destruction. Treatment modalities can be divided into surgical and nonsurgical therapies, although surgical therapy is the mainstay of treatment. Superficial therapies, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, or cryotherapy, may be effective for anatomically challenging locations where surgery or radiation is contraindicated, but the cure rates of these approaches are lower compared with surgery. Recent FDA-approved hedgehog pathway inhibitors include vismodegib and sonidegib for patients who have exhausted surgical and radiation options for treating advanced BCC. This review contains 4 figures, 5 tables, and 25 references. Key words: cryosurgery, cutaneous basal cell carcinoma, hedgehog pathway inhibitors, Mohs micrographic surgery, pathologic risk factors, photodynamic therapy, radiation therapy, surgical margins, topical therapies 

scholarly journals Neglected Basal Cell Carcinomas in the 21st Century

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Erika Varga ◽  
Irma Korom ◽  
Zoltán Raskó ◽  
Erika Kis ◽  
János Varga ◽  
...  
Keyword(s):  
21St Century ◽  
Basal Cell ◽  
Multidisciplinary Approach ◽  
Skin Neoplasms ◽  
Metastatic Potential ◽  
The Elderly ◽  
Treatment Modalities ◽  
Basal Cell Carcinomas ◽  
Cutaneous Tumor ◽  
The Ideal

Although tumors on the surface of the skin are considered to be easily recognizable, neglected advanced skin neoplasms are encountered even in the 21st century. There can be numerous causes of the delay in the diagnosis: fear of the diagnosis and the treatment, becoming accustomed to a slowly growing tumor, old age, a low social milieu, and an inadequate hygienic culture are among the factors leading some people not to seek medical advice. The treatment of such advanced neoplasms is usually challenging. The therapy of neglected cases demands an individual multidisciplinary approach and teamwork. Basal cell carcinoma (BCC), the most common cutaneous tumor, usually develops in the elderly, grows slowly, and has an extremely low metastatic potential; these factors are suggesting that BCCs might well be the “ideal candidates” for neglected tumors. Five neglected advanced cases of BCC were diagnosed in our dermatological institute between 2000 and 2009. The clinical characteristics and treatment modalities of these neoplasms are discussed, together with the possible causes of the neglect.

scholarly journals Current Devices in TMVI and Their Limitations: Focus on Tendyne

2020 ◽  
Vol 7 ◽  
Author(s):  
Gry Dahle
Keyword(s):  
United States ◽  
Mitral Valve ◽  
Treatment Options ◽  
Mitral Valve Regurgitation ◽  
Paravalvular Leak ◽  
Western World ◽  
Transcatheter Aortic Valve ◽  
High Incidence ◽  
Valve Implantation ◽  
Annular Calcification

Mitral valve regurgitation (MR) has a high incidence in the western world, and mortality is high for untreated severe MR. Catheter based repair was introduced with MitraClip in 2003, and some additional devices later came into the market. To expand the transcatheter treatment options for mitral valve disease, the first transcatheter mitral valve implantation (TMVI) was performed by Søndergaard et al. 2012, only 10 years after the first transcatheter aortic valve implantation (TAVI), however, the development has been much slower for the TMVI than for TAVI. From 2012, studies were started for several devices to prove feasibility and safety. However, there were big challenges in valve design; delivery systems and anchoring in addition to anatomical issues (avoid LVOT obstruction and paravalvular leak, big size of annulus). The main valves in studies were CardiaQ (later bought by Edwards Lifesciences, Irvine, United States), Tiara (Neovasc Inc., Richmond, Canada), Twelve (later Intrepid, Medtronic, MN, United States) and Tendyne™ (Abbott, MN, United States). I will focus on the Tendyne™ valve that is the only CE approved transcatheter mitral valve implant. It is available in a large number of sizes and is repositionable and retrievable. The results for the 100 first patients included in the early feasibility study (EFS) at 1 and 2 years are promising. Initially feasible for MR, but further investigations show promising results also for implant in mitral annular calcification.

High incidence of demodicidosis in eyelid basal cell carcinomas

2003 ◽  
Vol 42 (7) ◽  
pp. 567-571 ◽  
Author(s):  
Zulal Erbagci ◽  
Ibrahim Erbagci ◽  
Suna Erkilic
Keyword(s):  
Basal Cell ◽  
High Incidence ◽  
Basal Cell Carcinomas

scholarly journals Current and Prospective Treatment of Adenomyosis

2021 ◽  
Vol 10 (15) ◽  
pp. 3410
Author(s):  
Fady I. Sharara ◽  
Mira H. Kheil ◽  
Anis Feki ◽  
Sara Rahman ◽  
Jordan S. Klebanoff ◽  
...  
Keyword(s):  
English Language ◽  
Treatment Options ◽  
Treatment Algorithm ◽  
Treatment Modalities ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Pubmed Search ◽  
Surgical Treatments ◽  
Uniform Treatment ◽  
Standardize Treatment

(1) Background: Adenomyosis is a poorly understood entity which makes it difficult to standardize treatment. In this paper we review and compare the currently approved medical and surgical treatments of adenomyosis and present the evidence behind them. (2) Methods: A PubMed search was conducted to identify papers related to the different treatments of adenomyosis. The search was limited to the English language. Articles were divided into medical and surgical treatments. (3) Results: Several treatment options have been studied and were found to be effective in the treatment of adenomyosis. (4) Conclusions: Further randomized controlled trials are needed to compare treatment modalities and establish a uniform treatment algorithm for adenomyosis.

Sign in / Sign up

Export Citation Format

Share Document